If you want to compare how much more has been completed compared with the FY19 report read this:
Clinical progress The Company is greatly encouraged by these advances, which have been pivotal in the delivery of further intravenous infusion study safety data in small animals, indicating a wide therapeutic dose window. Positive kidney and urinary tract infection efficacy data indicates the potential use of RECCE® 327 across the full therapeutic approach to the treatment of patients with sepsis. With a compelling data package, the business is on track to formalise a clinical trial agreement to start a first-in-human Phase I trial and, submit an application to start a topical Phase I/II trial. We look forward to providing updates as these programs advance.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)